In highly specialised settings, a clinician might theoretically consider combining a GH-axis modulator with an incretin-based therapy for a patient with a specific, well-characterised metabolic phenotype for instance, significant visceral adiposity in the context of HIV-associated lipodystrophy who has not responded adequately to standard treatments
Heres how it works
Peptide therapy, for example, can be taken orally when the primary goal is gut health
Kolchina N, Khavinson V, Linkova N, et al
When treated with 5FU, cancer cells specifically increase mitochondrial content to buffer nucleotide stress, whereas stromal cells do not, meaning that cancer cells become intrinsically more dependent on mitochondrial metabolism
The valence band maximum of NGODs is positioned at 1.78 V (vs